ramatroban

thromboxane A2 receptor antagonist; BAY u 3405 & 3406 are enantiomers of each other; structure in first source

Also Known As:

3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; BAY u 3405; BAY u 3406; BAY u-3405; BAY u3405; 9H-Carbazole-9-propanoic acid, 3-(((4-fluorophenyl)sulfonyl)amino)-1,2,3,4-tetrahydro-, (R)-

Networked: 58 relevant articles (8 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gupta, Ajay: 4 articles (01/2022 - 01/2020)
2.	Kostenis, Evi: 4 articles (02/2007 - 02/2005)
3.	Ulven, Trond: 4 articles (02/2007 - 02/2005)
4.	Hirai, Hiroyuki: 3 articles (05/2015 - 03/2005)
5.	Mathiesen, Jesper Mosolff: 3 articles (02/2007 - 08/2005)
6.	Shichijo, Michitaka: 3 articles (01/2004 - 04/2003)
7.	Chiang, Kate C: 2 articles (01/2022 - 01/2022)
8.	Imig, John D: 2 articles (01/2022 - 01/2022)
9.	Kalantar-Zadeh, Kamyar: 2 articles (01/2022 - 01/2020)
10.	Reddy, Srinivasa T: 2 articles (01/2022 - 01/2020)

Related Diseases

1.	Allergic Rhinitis 01/01/2020 - "Ramatroban, used for the treatment of allergic rhinitis in Japan for the past 20 years has an excellent safety profile. " 01/01/2011 - "These results indicate that epinastine and ramatroban induce the prophylactic effect on allergic rhinitis." 04/01/2006 - "Ramatroban, a thromboxane A2 receptor antagonist with clinical efficacy in allergic rhinitis, was recently found to also display potent CRTH2 antagonistic activity. " 01/01/2022 - "Ramatroban is an orally bioavailable, dual thromboxane A2/TP and prostaglandin D2/DP2 receptor antagonist used in Japan for allergic rhinitis. " 08/01/2017 - "The CRTH2 antagonist (OC000459) or dual CRTH2 and TP receptor antagonist (ramatroban) were effective in reducing eosinophilia, nasal mucosal swelling, and clinical symptoms of allergic rhinitis, with the latter drug registered for clinical use in this indication. "
2.	Atherosclerosis 01/01/2004 - "Therefore, ramatroban may be beneficial in the treatment of atherosclerosis." 01/01/2022 - "Ramatroban, a dual blocker of TP and DP2 receptors, has demonstrated efficacy in animal models of respiratory dysfunction, atherosclerosis, thrombosis, and sepsis, as well as preliminary evidence for rapid relief from dyspnea and hypoxemia in COVID-19 pneumonia. "
3.	Nasal Obstruction 04/01/1993 - "BAY u 3405 afforded no protection against PG D2-induced nasal blockage. " 04/01/1993 - "The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin D2-induced nasal blockage." 06/01/1998 - "1. TxA2 receptor (TP-receptor) antagonists such as S-1452 and Bay u 3405 have been shown to be effective in alleviating nasal blockage in patients with allergic rhinitis as well as guinea-pig allergic rhinitis models. "
4.	Thrombosis (Thrombus) 10/18/1993 - "In six baboons, a bolus injection of Bay U3405, calculated to attain an initial plasma concentration of 300 ng/ml, reduced the maximum thrombus formation measured over a 2 h study period. " 10/18/1993 - "The aim of this study was to determine if Bay U3405 could be used to inhibit arterial thrombosis. " 06/01/1993 - "BAY U 3405 prevented primary arterial thrombosis, corresponding to inhibition of platelet aggregation, and increased bleeding times. " 06/01/1993 - "Ex vivo platelet aggregation was inhibited, bleeding time increased, and thrombus weight reduced after BAY U 3405 treatment. " 06/01/1993 - "BAY U 3405 administration prevented occlusive arterial thrombosis formation. "
5.	Septic Shock (Toxic Shock Syndrome) 08/01/1994 - "Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock." 08/01/1994 - "The present study was designed to investigate the effects of BAY U 3405, a new thromboxane A2 (TxA2) receptor antagonist, in endotoxin shock. " 11/01/1995 - "Employing a thromboxane A2 (TXA2) receptor antagonist (BAY U 3405) in the presence of LD100 Escherichia coli challenge, we blocked the acute pulmonary hypertensive phase and prevented early mortality, however, TXA2 blockade did not affect the latter development of septic shock and death. "

Related Drugs and Biologics

1.	Thromboxane Receptors (Thromboxane Receptor)
2.	ramatroban
3.	Prostaglandin D2
4.	Thromboxanes
5.	Prostaglandin H2 Thromboxane A2 Receptors
6.	S 145
7.	(5- fluoro- 2- methyl- 3- quinolin- 2- ylmethylindo- 1- yl)acetic acid
8.	Thromboxane A2 (A2, Thromboxane)
9.	Histamine (Histamine Dihydrochloride)
10.	Collagen

Related Therapies and Procedures

1.	Immunotherapy
2.	Chemoprevention
3.	Therapeutics